Understanding Daily Changes in BDD Risk Using Smartphones

NCT ID: NCT04254575

Last Updated: 2023-09-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

87 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-07-15

Study Completion Date

2023-04-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Body dysmorphic disorder (BDD) is associated with high risk for suicide attempts (22-28%) and substance use disorders (49%), underscoring the importance of accurate, real-time risk detection in BDD. This study aims to use smartphone-based digital phenotyping to develop and validate unobtrusive, time-sensitive, and ecologically valid measures of key risk factors for suicide and substance misuse in BDD: negative affect states. As next steps, this research can be extended to detect risk transdiagnostically, with the goal of enabling just-in-time interventions to target suicide and substance misuse across psychiatric illnesses.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Body Dysmorphic Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

body dysmorphic disorder (BDD)

Adults with a current primary diagnosis of body dysmorphic disorder (BDD)

None, observational study only (no interventions)

Intervention Type OTHER

None, observational study only (no interventions)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

None, observational study only (no interventions)

None, observational study only (no interventions)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults age \>=18
* Current primary diagnosis of BDD
* BDD severity \>= moderate
* Living in US
* English proficiency
* Owns an Android or iOS (Apple) smartphone
* Has regular Wifi-enabled internet access for data downloads
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Massachusetts General Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hilary Weingarden

Psychologist

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hilary Weingarden, PhD

Role: PRINCIPAL_INVESTIGATOR

Massachusetts General Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Massachusetts General Hospital

Boston, Massachusetts, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Weingarden H, Jaroszewski AC, Armey M, Hoeppner BB, Armstrong CH, Onnela JP, Wilhelm S. Predicting concurrent and short-term desire and intent to attempt suicide among people with body dysmorphic disorder using ecological momentary assessment of anxiety and shame. J Psychopathol Clin Sci. 2025 Oct 6. doi: 10.1037/abn0001054. Online ahead of print.

Reference Type DERIVED
PMID: 41051851 (View on PubMed)

Weingarden H, Meng X, Armey M, Onnela JP, Jaroszewski A, Armstrong CH, Wilhelm S. Predicting the strength of next-day negative emotion states in body dysmorphic disorder using passive smartphone data: An intensive longitudinal assessment study. Internet Interv. 2025 May 15;40:100833. doi: 10.1016/j.invent.2025.100833. eCollection 2025 Jun.

Reference Type DERIVED
PMID: 40486130 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2019P002041

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.